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Abstract
Background This study aimed to assess whether endo-
scopic implantation of an injectable esophageal prosthesis,
the Gatekeeper Reflux Repair System (GK), is a safe and
effective therapy for controlling gastroesophageal reflux
disease (GERD).
Methods A prospective, randomized, sham-controlled,
single-blinded, international multicenter study planned
final enrollment of 204 patients in three groups: up to 60
lead-in, 96 GK, and 48 sham patients. The sham patients
were allowed to cross over to the GK treatment arm or exit
the study at 6 months. The primary end points were (1)
reduction in serious device- and procedure-related adverse
device effects compared with a surgical composite com-
plication rate and (2) reduction in heartburn symptoms
6 months after the GK procedure compared with the sham
procedure. The secondary end point was improved esoph-
ageal pH (total time pH was \4) 6 months after the GK
procedure compared with baseline.
Results A planned interim analysis was performed after
143 patients were enrolled (25 lead-in, 75 GK, and 43 sham
patients), and the GK study was terminated early due to
lack of compelling efficacy data. Four reported serious
adverse events had occurred (2 perforations, 1 pulmonary
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infiltrate related to a perforation, and 1 severe chest pain) at
termination of the study with no mortality or long-term
sequelae. Heartburn symptoms had improved significantly
at 6 months compared with baseline in the GK group
(p \ 0.0001) and the sham group (p \ 0.0001), but no
significant between-group difference in improvement was
observed (p = 0.146). Esophageal acid exposure had
improved significantly at 6 months compared with baseline
in the GK group (p = 0.021) and the sham group
(p = 0.003), but no significant between-group difference in
improvement was observed (p = 0.27).
Conclusions The GK procedure was associated with some
serious but infrequent complications. No statistically sig-
nificant difference in outcomes was observed between the
treatment and control groups at 6 months compared with
baseline.
Keywords Gastroesophageal reflux disease 
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Symptoms associated with gastroesophageal reflux disease
(GERD) are common, with an incidence of approximately
20% in the general population [1]. Findings show that GERD
has a substantial impact on patient quality of life and use of
health care resources [2]. The pathophysiology of GERD is
multifactorial and often includes low resting pressure of the
lower esophageal sphincter (LES) and occurrence of tran-
sient LES relaxations. This episodically exposes the esoph-
ageal body to gastric acid and enzymes [3]. Usually, GERD
manifests as heartburn and regurgitation, predisposing the
patient to the development of esophagitis, Barrett’s meta-
plasia, and esophageal adenocarcinoma [4].
The current therapy for GERD begins with lifestyle
changes and medical treatment, which prove to be adequate
or effective for more than 90% of patients. Such therapy
usually must be maintained long term because the rate for
recurrence of symptoms is as high as 90% after cessation of
medication. In addition, long-term drug therapy is associated
with issues of cost, compliance, and long-term safety [5].
Patients who do not tolerate medication, respond inad-
equately to medication, or wish to avoid life-long drug
therapy may be considered as candidates for surgery. Such
surgery necessitates general anesthesia, has a mortality rate
of approximately 0.2%, and can be associated with addi-
tional morbidity including dysphagia, gas-bloat syndrome,
and postprandial fullness [6].
Over the past few years, several endoscopic therapies
have been proposed for the treatment of GERD. These
minimally invasive procedures use three different approa-
ches in an attempt to improve the antireflux barrier function:
(1) injection of filler materials into the LES and cardia
[7–9], (2) delivery of radiofrequency energy to the LES and
cardia [10], and (3) creation of gastroplications [11, 12].
Multiple other techniques such as the His-Wiz infra-
sphincteric plicator [13], use of magnets to augment the
esophageal sphincter [14], or implantation of an on-demand
microstimulator into the LES to increase LES pressure [15]
are under study. These endoluminal techniques may provide
an alternative to long-term maintenance therapy with proton
pump inhibitors (PPI) or surgery.
The Gatekeeper Reflux Repair System (Medtronic, Inc.,
Shoreview, MN, USA) offers an injectable technique that
uses polyacrylonitrile-based hydrogel prostheses placed
into the esophageal submucosal space at the level of the
LES to prevent reflux. The procedure is performed endo-
scopically on an outpatient basis. The current study aimed
to compare esophageal submucosal implantation of a
hydrogel prosthesis (Gatekeeper Reflux Repair System)
and a sham procedure in terms of therapeutic efficacy and
safety.
Methods
Study objectives
The primary safety end point was reduction in serious
device- and procedure-related adverse device effects
compared with a surgical procedure composite complica-
tion rate of 15%. The primary efficacy end point was
reduction in heartburn symptoms (calculated using the first
9 scales from the GERD-HRQL [health-related quality of
life] questionnaire) 6 months after the procedure compared
with the control group. The secondary efficacy end point
was improved esophageal pH, defined as the total per-
centage of time that pH was lower than 4 at 6 months after
the Gatekeeper procedure compared with baseline.
Study design
The Gatekeeper trial was a prospective, randomized, sham-
controlled, single-blinded, international, multicenter study.
Participants were recruited from 11 centers (10 in the
United States and 1 in Europe). The inclusion and exclu-
sion criteria are presented in Table 1. The study was
approved by the investigational review board or the sci-
entific and ethical committee for all the study sites, and all
the patients were provided written informed consent before
enrollment. During the initial training of investigators (all
treated with Gatekeeper prostheses), 25 patients were
treated as lead-ins. The lead-in patients met the same eli-
gibility criteria and underwent the same pre- and postpro-
cedure evaluations as the randomized patients. They were,
however, not blinded to their therapy, so they were not
included in the efficacy analysis.
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Patients were randomized to receive Gatekeeper pros-
theses in the treatment arm or a sham procedure in the
control arm of the study. All the patients were asked to
continue their current PPI therapy for 2 weeks after the
Gatekeeper or sham procedure. After the 2-week period, all
the patients were asked to discontinue their PPI therapy.
The patients who had persistent symptoms of heartburn or
regurgitation (defined as requiring antacid use at least 3 or
4 times per week) were given antireflux medication using
the following treatment regimen, which progressed at 1- to
2-week intervals:
1. Unlimited use of antacids of the patient’s choice; if
symptoms persisted, the patient could take over-the-
counter H2-blockers to control symptoms.
2. Prescription H2-blockers (at therapeutic doses) and
antacids (as needed).
3. PPIs as needed.
4. PPIs at a therapeutic dose per patient requirement.
The patients in the Gatekeeper arm of the study were
implanted initially with four Gatekeeper prostheses. At
3 months, the patients were eligible for retreatment with up
to four additional prostheses if symptom control was
unsatisfactory (GERD-HRQL [ 15). To maintain the
blind, the patients in the sham arm of the study were
offered re-sham procedures if symptom control was
unsatisfactory at 3 months (GERD-HRQL [ 15). At
6 months, the patients in the sham arm of the study were
allowed to cross over to the Gatekeeper treatment arm or to
exit the study. The study design is shown in Fig. 1.
Gatekeeper procedure
Conscious or deep sedation was administrated according to
the standard practices of the study centers for upper gas-
trointestinal endoscopy. The Gatekeeper procedure used a
16-mm overtube as a conduit for the endoscope and the
2.4-mm-diameter hydrogel delivery system (Fig. 2).The
endoscope (contained within the lumen of the overtube)
and overtube were passed into the lower esophagus over a
guidewire. Once these were in position, suction was
applied via the endoscope, which pulled the esophageal
wall into a shelf at the end of the overtube.
Next, the injection needle was passed through a second
channel in the overtube, and 3–6 ml of saline was injected
into the tissue, which had been stabilized previously in the
shelf, creating a tissue bleb in the submucosal space. The
injection needle was removed, and the prosthesis delivery
system (1-mm-diameter needle, dilator, and 2.4-mm-
diameter sheath) was passed through the same channel and
advanced into the tissue bleb. The needle assembly and
dilator then were removed, leaving the sheath in the
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age C 18 years old and typical persistent GERD
symptoms (heartburn, regurgitation, or both). All
patients showed symptomatic improvement with PPI
and wanted to discontinue their GERD medications
Baseline GERD-HRQL heartburn score of B11 on PPI
and C20 off PPI (all GERD-related drugs were
stopped for a minimum of 7 days minimum before
completion of the off-medication GERD-HRQL
questionnaire)
Pathologic esophageal acid exposure at pH testing using
the Bravo pH test (baseline 24-h pH, C4% of the time
with a pH B 4.0); a standard meal consisting of a
hamburger, cheeseburger or chicken burger, French
fries, and a milkshake was consumed within each 24-h
period of the 48-h pH monitoring
A negative pregnancy test for females of childbearing
potential within 1 week before treatment
Dysphagia
Morbid obesity (BMI [ 35 kg/m2)
Severe esophagitis (grade C or D LA classification)
Previous esophagogastric surgery, antireflux procedures, or
gastroesophageal or gastric cancer
Hiatus hernia [ 3 cm
Barrett’s esophagus [ 2 cm
Ineffective esophageal motility (defined as amplitudes of esophageal
peristalsis of \30 mmHg [ 50% of the time)
Esophageal or gastric varices
Esophageal strictures
Increased anesthesia risk (ASA Physical Status Classification 3 or 4)
Immunocompromised status
Stroke or transient ischemic neurologic attach within the 6 months
before enrollment
A significant gastrointestinal bleed with the 6 months before
enrollment
Other significant disease that may cause patient noncompliance
Coagulation disorder
Simultaneously participation in another drug or device study
GERD gastroesophageal reflux disease, BMI body mass index, HRQL health-related quality of life, LA Los Angeles, PPI proton pump inhibitor,
ASA American Society of Anesthesiology
Note: The primary reason for screen failure was due to disqualifying GERD-HRQL scores either off or on PPIs
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submucosal plane. Next, a dry hydrogel rod 1.0–1.8 mm in
diameter and 10–15 mm long was loaded into the proximal
end of the sheath and advanced with a push rod through the
sheath into the submucosa. Once the hydrogel was deliv-
ered, the push rod and sheath were removed.
For additional deliveries, the overtube and endoscope
assembly were rotated approximately 908, and the process
was repeated. Up to four prostheses were implanted during
the initial implantation procedure. The complete procedure
required approximately 15 min for the first hydrogel
implant and 5 min for each additional implant. Within
24 h, the hydrogel implants were fully expanded, creating
pillow-like mounds in the esophageal wall or cardia sub-
mucosa, which bulged into the lumen, thus creating a
potential mechanical antireflux barrier.
The sham group underwent upper gastrointestinal
endoscopy with conscious or deep sedation. The sham
procedure was performed using the same system to
simulate delivery, but without injection of saline,
advancement of the needle into tissue, or insertion of
prostheses.
The patients randomized to the Gatekeeper technique
were given intravenous antibiotics during the procedure. The
patients randomized to the sham procedure were given 50 ml
of normal saline intravenously in place of the antibiotic.
Statistical analysis
The primary efficacy end point, heartburn symptoms, was
analyzed using either a two-sample t-test or a Wilcoxon
rank-sum test, as appropriate. The analysis measured the
changes in the HRQL questionnaire heartburn questions
between baseline and 6 months, then compared the chan-
ges between the study and control groups. The primary
safety and efficacy end points had to be met for the study to
be considered successful.
Gatekeeper Study Initial Enrollment: 
395
2 Week Follow-up:  Phone
3 Month Follow-up:  
Endoscopy, 
Questionnaires Retreatment 
Allowed (HRQL>15)
6 Month Follow-up:  
Endoscopy, Manometry, 
pH, Questionnaires         
Blind Broken
12 Month Follow-up:  
Endoscopy, Manometry, 
pH, X-ray, Questionnaires
24 Month Follow-up:  
Phone
2 Week Follow-up:  Phone
3 Month Follow-up:  
Endoscopy, 
Questionnaires Resham 
Allowed (HRQL>15)
6 Month Follow-up:  
Endoscopy, Manometry, 
pH, Questionnaires
Blind Broken
Study                    
Exit:   
143
Gatekeeper Implant: 75
Baseline:  Questionnaires 
on/off meds, Endoscopy, 
Manometry, Bravo pH, Labs, X-
ray, Physical, Medical History
Sham Procedure: 43
6 Week Follow-up:      
Questionnaires
6 Week Follow-up:      
Questionnaires
Randomized: 
118   
During procedure
Sham  
X-over: 24 
Gatekeeper Implant: 25
Lead-in Subjects: 
25
Not Blinded to Therapy 
Screen Failures: 
218
In Screening at Time of 
Early Study Termination: 
34
Fig. 1 At 6 months, the
blinding was broken, and the
patients in the sham group were
given the option to cross over to
the Gatekeeper group or exit the
study
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Improvement in esophageal pH, defined as the total
percentage of time that the pH was less than 4, was
calculated, and other analyses (DeMeester Score, Medical
Outcomes Survey Short Form 36 [SF-36], HRQL regur-
gitation score, and LES pressure) were performed using
the same tests as described earlier. Improvement in
esophageal pH was analyzed using the average of two
sequential 24-h periods of wireless esophageal pH mon-
itoring (Bravo pH Monitoring System; Medtronic Inc.).
All p values 0.05 or less were considered statistically
significant.
Results
The study initially enrolled 395 patients from 24 Septem-
ber 2003 to 30 September 2005. A total of 252 patients
failed to reach randomization primarily due to disqualify-
ing HRQL scores on or off PPIs. Up to three patients per
investigator were planned to be treated as lead-ins. Ran-
domization was planned for 144 patients, with 96 patients
to receive the Gatekeeper prosthesis and 48 patients to be
in the sham control group. A planned interim analysis was
performed after 143 patients were enrolled including 25
lead-ins and 118 randomized (75 Gatekeeper and 43 sham)
patients.
The Gatekeeper study was terminated early due to lack
of compelling efficacy data. The blinding was broken for
all the patients in the study, and no further Gatekeeper
implantations were allowed including new randomization,
month 3 reimplantations, and cross-over of sham patients
to the Gatekeeper arm of the study. All 143 lead-in and
randomized patients exited the study. The majority of
patients exited the study, with 78 completing the study, 22
electing to have their prostheses removed, 16 withdrawing
consent, 12 needing to leave when Medtronic closed the
study, 11 lost to follow-up evaluation or lacking efficacy;
and 4 having other causes. The study had 6-month follow-
up data available for 51 (68%) of 75 patients in the Gate-
keeper group and 26 (60%) of 43 patients in the sham
group.
Originally, implant removal was performed for patients
who desired it. After removal of the implants from 21
patients resulted in one perforation, one near perforation,
and noted discrepancies between the number of prostheses
implanted and the number of prostheses explanted,
Medtronic reassessed the explantation procedure and
prostheses visualization techniques. This led to a change in
Fig. 2 Gatekeeper procedure. a The esophageal wall is aspirated. b Normal saline is injected into the submucosal layer. c A pocket is created
into the submucosal layer. d The prosthesis is implanted in the pocket. e Hydrated prostheses in situ 24 h after implantation are shown
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recommendation advising that explantations should be
performed only if medically necessary, that a computed
tomography (CT) scan should be performed before
explantation to identify the number and orientation of
prostheses, that only prostheses clearly visible endoscopi-
cally should be removed, and that the explantation site
should be closed with endoscopic clips. To assess for
perforation, nothing by mouth was received and an X-ray
using water-soluble contrast was performed after explan-
tation at the discretion of the physician.
For the patients randomized to the Gatekeeper treatment
group, the implantation success rate was 92%. At
3 months, 44.4% of the implanted randomized patients
were retreated with additional implants. Retreatment at
3 months was performed for 40% of the lead-in patients. At
6 months, 24 patients (56%) in the sham group crossed
over to the Gatekeeper group, whereas 18 sham patients did
not cross over due to early study closure. One sham patient
elected to exit the study without crossing over. The Gate-
keeper prostheses retention rate, defined as the number of
prostheses seen at follow-up endoscopy compared with the
initial number implanted, was 73% at 6 months and 63% at
12 months respectively.
Primary safety outcome: device- or procedure-related
adverse events 6 months after the Gatekeeper
procedure
The hypothesis test for adverse events was not performed
due to early cessation of the study. At the time of study
termination, four device- or procedure-related complica-
tions in 124 implanted subjects qualified as serious adverse
events. These included esophageal wall perforations in two
patients, pulmonary infiltrate related to a perforation in one
patient, and severe chest pain in one patient. The overall
serious device- or procedure-related adverse event rate was
3.2%, with a 95% upper confidence limit of 7.2%.
A lead-in patient experienced the first perforation, caused
by a Savory guidewire used to pass the overtube during
device implantation. Esophageal wall tear occurred, and the
patient had an emergency thoracotomy and was admitted to
the intensive care unit for 4 days, with an additional 6-day
hospital stay. No long-term sequelae occurred.
The second esophageal perforation occurred in the
Gatekeeper group after removal of the prostheses via
needleknife incision over a prosthesis. The patient had
severe retrosternal pain after the procedure. The chest
X-ray showed a suspicion of mediastinal air. The esopha-
gogram with water-soluble contrast showed no mediastinal
leakage. The patient was admitted to the hospital and
treated with antibiotics as well as nothing by mouth. No
further intervention was performed. A follow-up chest
X-ray showed pulmonary infiltrate and pleural effusion,
which were considered the third severe adverse event due
to prolongation of the hospital stay. The patient was
discharged after 11 days.
The fourth reported serious adverse event was severe
substernal chest pain after device implantation. The patient
presented to the emergency department the night of the
procedure with intense substernal stabbing pain. A chest X-
ray and a barium esophagram showed no abnormalities.
The patient received narcotics for pain and was kept
overnight for observation, then released the next day
without sequelae.
No serious adverse events occurred in the sham group.
Minor complications were reported in all the treatment
groups. The most common minor complications were
esophageal erosions over the Gatekeeper prostheses, tran-
sient nausea and vomiting, dysphagia, chest pain, sore
throat, and abdominal pain (Table 2).
Primary efficacy outcome: heartburn symptoms
improvement 6 months after the procedure compared
with the control group
Compared with baseline, a significant improvement in
heartburn symptoms (calculated using the first 9 questions
from the GERD-HRQL questionnaire) was observed at
6 months in the Gatekeeper (p \ 0.0001) and sham
(p \ 0.0001) groups (Table 4). However the improvement
in the Gatekeeper group was not better than in the sham
group (p = 0.146; Table 4). At 12 months, the improve-
ment in heartburn symptoms in the Gatekeeper group
continued to be significant (p \ 0.0001; Table 5).
Secondary efficacy outcomes: improvement
in esophageal pH 6 months after the Gatekeeper
procedure compared with baseline
The mean esophageal acid exposure times were abnormal
for many parameters in both groups at baseline (Table 3).
The Gatekeeper and sham groups showed significant
improvement in esophageal acid exposure at 6 months
compared with baseline, as indicated by Bravo pH moni-
toring (p = 0.021 and 0.003, respectively; Table 4).
However, the improvement in esophageal acid exposure in
the Gatekeeper group was not significantly better than in
the sham group at 6 months (p = 0.270; Table 4).
Additional analysis
Regurgitation symptoms
Compared with baseline, a significant improvement in
regurgitation symptoms (calculated using questions 10–15
1392 Surg Endosc (2010) 24:1387–1397
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from the GERD-HRQL questionnaire) was observed at
6 months in the Gatekeeper (p \ 0.0001) and sham
(p = 0.0003) groups (Table 4). However, no difference in
improvement between the Gatekeeper and sham groups was
observed at 6 months (p = 0.330; Table 4). At 12 months,
the regurgitation symptoms improvement still was signifi-
cant in the Gatekeeper group (p = 0.0003; Table 5).
Esophageal manometry (LES pressure)
No statistically significant improvement in LES pressure
compared with baseline was observed in the Gatekeeper
group at 6 months (p = 0.079) and 12 months (p = 0.246)
(Tables 4, 5). The sham group showed a nonsignificant
decrease in LES pressure (p = 0.162; Table 4). Significant
improvement was observed in the Gatekeeper group com-
pared with the sham group at 6 months (p = 0.026; Table 4).
DeMeester score
At baseline, the mean DeMeester scores were abnormal,
with no significant difference between the groups
(Table 3). Significant improvement in the mean DeMeester
score compared with baseline was observed in the Gate-
keeper (p = 0.001) and sham (p = 0.027) groups at
6 months (Table 4). However, the Gatekeeper group
showed no difference in improvement compared with that
of the sham group (p = 0.573; Table 4).
Table 2 Total number of device- and procedure-related adverse device effects and total number and percentage of patients with adverse events
throughout the study for each study group and for all the study groups combined
AE category Sham group Gatekeeper group Lead-in group Total events
(all) (n)
Events
(n)
Patients
(n)
Patients
(n = 43)
Events
(n)
Patients
(n)
% of Patients
(n = 75)
Events
(n)
Patients
(n)
% of Patients
(n = 25)
Erosions over prostheses 26 9 37.5a 82 23 30.7 18 8 32.0 126
Sore throat 9 7 16.3 14 13 17.3 4 3 12.0 27
Nausea/vomiting 1 1 2.3 15 12 16.0 6 6 24.0 22
Chest pain 5 3 7.0 20b 11 14.7 9 6 24.0 34
Cough 1 1 2.3 1 1 1.3 0 0 0.0 2
Dysphagia 3 2 8.3a 10 7 9.3 1 1 4.0 14
Epigastric pain 1 1 2.3 8 5 6.7 2 2 8.0 11
Odynophagia 1 1 2.3 6 5 6.7 0 0 0.0 7
Pulmonary infiltrate and
pleural effusion
0 0 0.0 1c 1 1.3 0 0 0.0 1
Prosthesis transmural
migration
1 1 4.2a 0 0 0.0 0 0 0.0 1
Hemorrhage 1 1 1.96 1 1 1.3 0 0 0.0 2
Perforation 0 0 0.0 1c 1 1.3 1c 1 4.0 2
Desaturation 1 1 2.3 1 1 1.3 1 1 4.0 3
Bloating 0 0 0.0 5 4 5.3 0 0 0.0 5
Hiccough 0 0 0.0 1 1 1.3 0 0 0.0 1
Headache 0 0 0.0 2 2 2.7 0 0 0.0 2
Mouth injury or pain
from overtube
1 1 2.3 1 1 1.3 2 2 8.0 4
Drowsiness 0 0 0.0 0 0 0.0 1 1 4.0 1
Low-grade fever 0 0 0.0 0 0 0.0 1 1 4.0 1
Deformed Anatomy at
GE junction
0 0 0.0 0 0 0.0 2 2 8.0 2
Rash 0 0 0.0 1 1 1.3 0 0 0.0 1
Misreported AEsd 1 1 2.3 1 1 1.3 2 1 4.0 4
Total 52 171 50 273
GE gastroesophageal, AEs adverse events
a The denominator is 24 (the number of Sham patients who crossed over to the Gatekeeper arm)
b One patient experienced severe chest pain, which was considered serious
c Considered a serious adverse event
d Four adverse events were reported as device or procedure related but were later adjudicated as not related
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SF-36
The general quality-of-life scores (SF-36 physical and
mental scores) at 6 months were significantly improved in
the Gatekeeper group for physical function (p = 0.006) but
not for mental function (p = 0.925), with the sham group
showing similar results (p = 0.002 and 0.325 respectively)
(Table 4). No difference in improvement of physical or
mental function was observed between the Gatekeeper
(p = 0.821) and sham (p = 0.347) groups at 6 months
(Table 4).
PPI consumption
At baseline, all the patients were taking daily PPIs (dose
equipotent or more potent than 20 mg omeprazole or its
equivalent). At 6 months, 55% of the patients in the
Gatekeeper group had stopped taking GERD medications,
specifically PPIs, H2 blockers, and prokinetics, compared
with 23% in the sham group (Gatekeeper vs sham treat-
ment, p = 0.008).
Discussion
The use of biocompatible materials as tissue-augmenting
agents is an established procedure that has been used for
many years in urology and dermatology [16–18]. As an
investigational approach, endoscopic bulking technology
for GERD dates back to the early 1980s [19, 20]. Lower
esophageal sphincter bulking therapies share a common
theoretical mechanism of action that involves increasing
wall thickness at the gastroesophageal junction and
reducing compliance of the LES. The ideal implant should
be biologically and chemically inert, nonmigrating, dura-
ble, and capable of inducing a negligible foreign body
reaction. Of the many injectable products available, En-
teryx [7], Gatekeeper [8], and plexiglass beads [9] have
been investigated for GERD.
Initial studies with a limited number of patients showed
that the Gatekeeper procedure significantly decreased
heartburn, improved quality of life, decreased 24-h
pH-metry scores, and decreased medication usage [21].
The success rate for implantation was 93%, whereas the
Table 3 Comparison of the two
treatment groups at baselinea
SD standard deviation, BMI
body mass index, HRQL health-
related quality of life, LES
lower esophageal sphincter, SF-
36 Medical Outcomes Survey
Short Form 36, PCS Physical
Component Scale, MCS Mental
Component Scale
a The two treatment groups
showed no statistically
significant difference at baseline
except for age and LES resting
pressure, which were greater in
the sham group
b Data were missing for two
Gatekeeper patients
Variable Gatekeeper group (n = 75) Sham group (n = 43) p Value
Gender: n (%)
Female 25 (33.3) 18 (41.9) 0.428
Male 50 (66.7) 25 (58.1)
Age (years)
Mean ± SD 47.9 ± 11.59 52.6 ± 11.80 0.035
Range (23.7–70.3) (23.5–76)
BMI
Mean ± SD 27.8 ± 3.39 27.5 ± 3.81 0.677
Range (19–35) (18.6–34.6)
Patients with hiatal hernia: n (%)b
None 25 (34.2) 16 (37.2) 0.516
1 cm 21 (28.8) 13 (30.2)
2 cm 17 (23.3) 12 (28)
3 cm 10 (13.7) 2 (4.6)
Patients with esophagitis: n (%)
None 66 (88) 40 (93) 0.795
Grade A 6 (8) 2 (4.67)
Grade B 3 (4) 1 (2.33)
Heartburn score per HRQL 26.9 ± 4.5 (20–42) 26 ± 4.77 (20–38) 0.296
Regurgitation score per HRQL 17.7 ± 7.38 (0–30) 17.7 ± 4.93 (5–27) 0.98
LES resting pressure per
manometry (mmHg)
13.4 ± 8.19 (0–36.6) 17.9 ± 11.32 (1–39.1) 0.017
Total % time pH was \4 12.4 ± 6.28 (3.5–43.5) 12.3 ± 5.81 (3.6–28.4) 0.902
DeMeester score 42.7 ± 21.39 (11.9–142.3) 41.6 ± 19 (13.3–102.6) 0.792
SF-36 PCS 45.2 ± 9.08 (22.6–59.8) 46.9 ± 8.62 (22.2–59.7) 0.316
SF-36 MCS 50.2 ± 11.02 (16.9–71.7) 51.2 ± 8.79 (28.2–63.6) 0.601
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procedural success rate was reported at 98.7% [22]. After
completion of a 6-month pilot study [8] with favorable
results, a European multicenter study was initiated [23].
The average number of prostheses implanted was 4.3
(range, 2–6). The final results showed significant
improvement in quality-of-life scores (HRQL score from
24 to 5), pH parameters (% of 24 h that pH was \4; 9.1%
decreased to 6.1%), and LES pressure (8.8 mmHg
improved to 13.8 mmHg) at 6 months. The prostheses
retention rate was 73% at 6 months. Of 40 patients, 2 (5%)
experienced severe complications including esophageal
perforation caused by overtube placement and severe
postprandial nausea leading to endoscopic removal of the
prostheses at 3 weeks.
Based on the relative efficacy and safety noted, a larger,
randomized, sham-controlled, single-blinded, multicenter
study of the Gatekeeper Reflux Repair System was initi-
ated. Although improvements in many parameters com-
pared with baseline were seen at 6 months in the sham and
active treatment groups, and although such improvements
persisted for 12 months in the active treatment group (with
no sham data available for comparison), the active treat-
ment was not superior to sham treatment with regard to the
efficacy of management of most GERD parameters. Such
limited efficacy compared with the sham procedure resul-
ted in early study termination.
One significant positive outcome for the active treatment
over that for the sham treatment was seen for medication
use. At 6 months, 55% of the patients in the active treat-
ment group were able to discontinue their PPIs completely,
compared with only 23% of the patients in the sham group
(p = 0.008). The quality-of-life scores (SF-36 and HRQL)
and 24-h pH monitoring were slightly improved in both
treatment groups. No significant improvement in LES
pressure was observed at the 6-month follow-up assess-
ment in the active treatment group. The negative results for
the objective response parameters in the active treatment
group contrasted with the significant reduction of heartburn
and regurgitation symptoms in the active treatment and
sham groups.
Some of the subjective and objective parameters in the
sham group showed statistically significant improvements.
Such a large sham effect may have been due to patient
education, with better management of GERD-provoking
behavior and continued use of permitted antacids
throughout the study. Additionally, the active and sham
patients completed the GERD-HRQL questionnaires after
cessation of medication therapy for only 7 days. This may
not have been adequate to ‘‘reactivate’’ GERD fully in the
sham group. Other studies on the endoscopic treatment of
GERD have seen a favorable therapeutic response in the
sham group in [24–27]. Studies longer than 6 months may
be needed to decrease the sham effect.T
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Preliminary animal studies and pilot human studies [8,
21–23] had suggested that the current Gatekeeper device
would be effective. The optimal number of prostheses, the
site of placement (above or below the squamocolumnar
junction), and the size of the implant were not known. No
human studies comparing various doses had been done. A
factor of ‘‘low dosing’’ in this study was the prostheses
retention rate of only 73% at 6 months and 63% at
12 months. Mucosal ulceration over the prostheses occur-
red in 32.3% of the patients. This likely had a significant
effect on the prostheses retention rate, accordingly reduc-
ing the treatment dose. Also, some technical issues of
implantation affected implantation success. The cardia is
acutely angulated at the angle of His. This made implant
delivery less successful in this quadrant because tissue was
more difficult to retain in the suction grove of the overtube.
It was uncertain whether respiratory movement affected
implantation technique. Visualization through the overtube
was required for implantation and was technically difficult.
Blood and secretions were unquantitated compromising
factors. These features may have presented significant
obstacles to accurate injection or implantation of the
prostheses. After implantation, visualization of the pros-
theses was difficult both endoscopically, due to the various
implantation depths, and on X-ray, due to the similarity of
prostheses to normal tissue.
This study also highlights the importance of careful,
well-designed, randomized, controlled trials (RCT) such as
the current trial for evaluating new medical devices. These
trials are of major importance in assessing the balance of
benefits and harm. Evidence that emphasizes only benefits
likely will lead to biased conclusions. The control group in
this type of RCT allows for monitoring of treatment effects
and adverse events associated with the intervention
throughout the trial. A challenge in studying endoscopic
interventions for GERD patients is ensuring the safety of
the participants.
In summary, this sham-controlled trial of endoscopic
implantation of Gatekeeper prostheses for GERD showed
that this procedure is associated with serious but infrequent
complications and improves GERD symptoms, quality of
life, and drug use for GERD patients at 6 months, with this
trend persisting for at least 12 months. The sham group
showed many similar improvements, however. The
improvements in esophageal functions (esophageal acid
exposure and LES pressure) in the active treatment group
were minimal and not clinically meaningful. Overall, no
statistically or clinically significant differences in outcomes
were observed between the treatment group and the control
group at 6 months compared with baseline (Table 4). For
this reason, the study was terminated early.
The concept of endoluminal treatment for GERD con-
tinues to be appealing because it focuses on gastroesoph-
ageal reflux control and not just acid secretory control [28,
29]. Currently effective medical and surgical therapies for
GERD create a relatively high standard for new endoscopic
therapies. To date, the major obstacles against their wider
spread use include limited to moderate efficacy for most
devices, lack of good reimbursement codes in the United
States, serious complications (although less frequent than
for fundoplication), and insufficient funding and support
for research to develop new technologies to treat GERD.
More work is needed before these approaches can be
considered a standard of care for GERD.
Additional studies are required to determine whether the
effectiveness of these techniques can be improved either by
increasing the therapy dose (using more sutures or
implanted material per session, better placement of pros-
theses, or multiple sessions) or by identifying diagnostic
parameters that better select patients likely to be
Table 5 Improvement in the Gatekeeper group at 12 monthsa
Variable N Baselineb 12 Monthsb Mean change, STD p Value
Heartburn (HRQL) 22 27.7 ± 4.8 (21–37) 14.8 ± 10.6 (1–34) -12.9, 10.5 \0.0001
Regurgitation (HRQL) 22 17.1 ± 9.2 (0–29) 8.7 ± 8.8 (0–24) -8.4, 9.2 0.0003
LES resting pressure (mmHg) 20 11.9 ± 7.2 (1–28.8) 14.5 ± 9.1 (4.3–33.4) 2.6, 9.8 0.246
Total % of time pH was \4 20 14.1 ± 8.8 (4.5–43.5) 13.3 ± 17 (2.3–83) -0.8, 18.6 0.114
DeMeester 20 48.9 ± 28 (15–142.3) 36.4 ± 19.9 (7.1–89.8) -12.4, 33 0.048
SF-36 PCS 21 44.6 ± 9 (27.3–59.8) 50.2 ± 9.2 (26.5–61.3) 5.6, 10.5 0.025
SF-36 MCS 21 54.3 ± 9.7 (39–71.7) 53.1 ± 6.2 (41.1–63.6) -1.2, 8.2 0.502
HRQL health-related quality of life, LES lower esophageal sphincter, SF-36 Medical Outcomes Survey Short Form 36, PCS Physical Component
Scale, MCS Mental Component Scale
a At 12 months, the improvement in the Gatekeeper group continued to be significant. Because the sham group either crossed over to the
Gatekeeper group or exited the study at 6 months, there was no sham comparison at 12 months
b Baseline and 12-month data only for Gatekeeper group patients who completed the 12-month follow-up questionnaire
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responders. Further refinement, development, and differ-
entiation of relatively simple, therapeutically effective,
cost-effective methods are anticipated.
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